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INTRODUCTION
Polyarteritis nodosa (PAN) is an uncommon systemic necro-
tizing vasculitis and is characterized by the presence of infla-
mmatory reactions of medium or small-sized blood vessels
with multi-organ involvements including skin, kidney, periph-
eral nerve, muscle, gastrointestinal tract and others (1, 2). PAN
was first described by Kussmaul and Maier in 1866 and many
reports have been issued on its clinical features. In Korea,
dozens of case reports and two papers on cutaneous PAN have
been published (3, 4). Although the prevalence of hepatitis
B is high in Korea and the association between PAN and hep-
atitis B is well known, no study about clinical features of sys-
temic PAN has been conducted. Thus we analyzed the clin-
ical features of classic PAN in Korea.
MATERIALS AND METHODS
Subjects
We searched the database of Seoul National University
Hospital for adult PAN patients (age ≥16 yr old) between
January 1990 and July 2003. Thirty six patients were first
suspected of having PAN and 27 of these satisfied the Ameri-
can College of Rheumatology (ACR) 1990 criteria for the
classification of PAN. Thus, 9 patients were excluded; 4 had
a limited form of PAN and five had a cutaneous form. All
limited and cutaneous PAN patients showed no evidence of
other organ involvement or of a saccular aneurysm by angio-
graphy. The male-to-female ratio was 1.7:1, mean age of onset
was 47.4±20 yr and the median follow up period was 55.5
months (range 0.6 -162 month). 
Methods
We retrospectively reviewed the medical records of 27 pati-
ents with PAN satisfying the ACR 1990 criteria. The para-
meters studied were gender, age, follow-up time, symptoms
and signs at onset, ACR criteria for PAN, organ involvement,
and laboratory findings. Symptoms and signs at onset includ-
ed; fever, arthralgia and arthritis, peripheral edema, abdom-
inal pain, hepatomegaly, subcutaneous nodule, lymphadeni-
tis, peripheral ischemia, and sinusitis.
The other clinical features according to the ACR criteria
were weight loss >4 kg, skin rash, testicular pain or tender-
ness, myalgia, weakness or leg tenderness, neuropathy, hyper-
tension, elevated blood urea nitrogen (BUN) or creatinine,
the presence of hepatitis B surface antigen (HBsAg) or hep-
atitis B surface antibody (HbsAb), an arteriographic and
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Clinical Features of Polyarteritis Nodosa in Korea
Polyarteritis nodosa (PAN) is a systemic vasculitis characterized by multi-organ in-
volvement with protean manifestations. We evaluated the clinical features of PAN
in Korea. Twenty-seven patients were diagnosed as PAN at Seoul National Uni-
versity Hospital between January 1990 and July 2003. The male-to-female ratio was
1.7:1 and mean age at onset (± ±SD) was 47.4± ±20 yr. Their presenting features
at diagnosis were similar to those reported previously, i.e., myalgia, muscle weak-
ness or leg tenderness (70%), fever (52%), weight loss >4 kg (44%), skin rash (44%),
peripheral edema (33%), abdominal pain (33%), and arthralgia/arthritis (30%). How-
ever, the prevalence of testicular pain or tenderness was higher (24%) than report-
ed previously and only three (11.5%) had HBsAg positivity without liver enzyme
elevation. Nine patients (33%) had a five-factor score (FFS) of 2. Fourteen patients
(52%) responded to treatment, 2 patients relapsed and 4 died within 1 yr of diagno-
sis. During a median follow-up of 55.5 months, three of the four PAN-related deaths
had an initial FFS of 2. The clinical features of PAN were not significantly different
from those reported previously. However, testicular pain or tenderness was more
frequent and patients with a high FFS tended to have a poorer prognosis.
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histopathologic abnormality. Organ involvement was divid-
ed into joint or muscle, peripheral nerve, skin, kidney, gas-
trointestinal tract, central nervous system, heart, and lung. 
In addition, laboratory tests at the time of diagnosis of PAN
included; hemoglobin, white blood cell and platelet counts,
Westergren erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), anti-streptolysin O (ASO), complement 3 (C3),
antinuclear antibody, rheumatoid factor, and antineutrophil
cytoplasmic antibody (ANCA). Angiographic and histopatho-
logic findings were also obtained. A positive angiographic
finding of PAN was defined as the presence of microaneurysm
or stenosis (narrowing or tapering) of medium-sized vessels,
and a positive pathologic finding was considered as focal seg-
mental necrotizing vasculitis of medium- and small-sized
arteries. 
For the treatment and prognosis of PAN, we analyzed med-
ications, response to medications, post-treatment recurrence
or death, and causes of death. A five-factor score (FFS) at the
time of diagnosis was calculated to evaluate the association
with mortality. These 5 factors were; proteinuria >1 g/day,
renal insufficiency (serum creatinine >1.58 mg/dL), gastroin-
testinal symptoms, cardiomyopathy, and centel nervous sys-
tem involvement (5-7). If patients were lost to follow at our
hospital, we interviewed them or their first-degree relatives
to check upon recurrence or cause of death. Kaplan-Meier
survival curves were plotted.
RESULTS
Clinical features 
The ages of patients were evenly distributed from 17 to
72 yr old. Clinical features at the time of diagnosis are sum-
marized in Table 1. Over half of the patients had fever at the
time of onset. The average number of 1990 ACR criteria per
patient was 4.67 (range 3-7), and the most prevalent items
were histopathologic abnormality (96%), and myalgia, weak-
ness and leg tenderness (70%), followed by neuropathy (63%),
positive HBsAg or HBsAb (56%), weight loss >4 kg (44%),
skin rash (44%), arteriographic abnormality (40%), elevat-
ed BUN or creatinine (30%), hypertension (30%) and tes-
ticular pain or tenderness (24%) (Table 2). 
The distribution of organ involvement was as follows; joint
or muscle (65%), peripheral nerve (63%), skin (44%), kid-
ney (48%), gastrointestinal tract (48%), central nervous sys-
Clinical features Number (%)
Fever 14/27 (52)
Arthralgia/arthritis 8/27 (30)
Peripheral edema 9/27 (33)
Abdominal pain 9/27 (33)
Hepatomegaly 5/27 (19)
Subcutaneous nodule 3/27 (11)
Lymphadenitis 2/27 (7)
Peripheral ischemia 3/27 (11)
Sinusitis 3/27 (11)
Table 1. Clinical features of polyarteritis nodosa patients at the
time of diagnosis
ACR criteria Number (%)
Weight loss >4 kg 12/27 (44)
Skin rash*  12/27 (44)
Testicular pain or tenderness  4/17 (24)
�
Myalgia, weakness or leg tenderness  19/27 (70)
Neuropathy 17/27  (63)
Hypertension 8/27  (30)
Elevated BUN or creatinine  8/27 (30)
Positive HBsAg or HBsAb  14/25 (56)
Arteriographic abnormality  8/20 (40)
Histopathologic abnormality  25/26 (96)
Table 2. Clinical features of polyarteritis nodosa patients accord-
ing to the American College of Rheumatology (ACR) 1990 cri-
teria
*Skin rash includes livedo reticularis (3/12), erythema nodosum (3/12),
and maculopapular rash (6/12). 
� Percentage in men. BUN, blood urea
nitrogen.
Laboratory parameter Number (%)
Hemoglobin <12 g/dL 10/27 (37)
WBC >12,000/ L 9/27 (33)
Thrombocyte >400,000/ L 7/27 (26)
Westergren ESR >40 mm/hr 14/27 (52)
CRP >0.5 mg/dL 16/27 (59)
ASO >1:400 Todd units 4/15 (27)
Elevated complement (C3) 3/24 (13)
Antinuclear antibody 7/26 (27)
Rheumatoid factor 8/26 (31)
Antineutrophil cytoplasmic antibody 5/26 (19)
Table 3. Laboratory findings of polyarteritis nodosa
WBC, white blood cell; CRP, C-reactive protein; ASO, antistreptolysin-O.
Manifestations
Cohen 
et al. (8)
1980
% (n=53)
Fortin 
et al. (9)
1995
% (n=45)
Guillevin
et al. (10)
1995
% (n=62)
Agard 
et al. (11)
2003
% (n=36)
Present
study
2005
% (n=23)
Fever 31 56 47 52
Weight loss 16 76 50 44
Peripheral nerves 60 51 60 75 63
Joints and muscles 51 65
Cutaneous 58 44 40 11 44
Renal 66 44 42 22 48
Hypertension 14 32 30
GI tract 25 53 45 53 48
Respiratory 13 40 29 6 4
CNS 24 2 11 7
Cardiac 4 18 8 17 7
Table 4. Clinical features of polyarteritis nodosa as reported pre-
viously
GI, gastrointestinal; CNS, central nervous system.Polyarteritis Nodosa in Korea 593
tem (7%), heart (7%), and lung (4%). Skin rash included
livedo reticularis (3 of 12), erythema nodosum (3/12), and
maculopapular rash (6/12).
When FFS was analyzed to evaluate its association with
PAN related mortality, 10 (37%) patients had an FFS of 0, 8
(29.6%) an FFS of 1, and 9 an FFS of 2 (33.3%). Of the 9
patients with an FFS of 2, four died. The hazard ratio (HR)
of mortality associated with an FFS=2 was 2.22 (Table 5). 
Laboratory findings
Laboratory findings are summarized in Table 3. Fourteen
(52%) patients had an elevated acute phase reactant (ESR >40
mm/hr or CRP >0.5 mg/dL). Fourteen (56%) patients were
HBsAg or HBsAb positive; however, only three among them
showed HBsAg positivity and they did not have elevated liver
enzymes. One of three HBsAg positive patients became neg-
ative for HBsAg but positive for anti-HBc antibody. Five
(19%) patients were ANCA positive; three c-ANCA and two
p-ANCA. Twenty-six patients underwent tissue biopsy of
muscle, nerve, skin, or GI tract. Histopathological findings
were necrotizing inflammation of medium-sized or small
arteries in 25 patients (Table 2). Twenty patients underwent
diagnostic angiography and 8 (40%) had positive angiogra-
phic findings for renal artery (5 cases), superior mesenteric
artery (2 cases), hepatic artery (1 case), brachial artery (1 case),
or tibial artery (1 case).
Treatment and prognosis
Treatment regimens included prednisolone alone (14 cases),
prednisolone plus cyclophosphamide (11 cases), prednisolone
plus other immunosuppressant (azathioprine, cyclosporine)
(2 cases). In our study, no one was treated with an HBV anti-
viral agent. 
One year after treatment, 14 patients (52%) responded to
their medication, 2 patients (7%) relapsed and 4 patients
(15%) died. Seven patients (26%) were lost to follow up and
their data were collected by telephone interviewing afterwards.
Of the patients who were lost to follow up, one relapsed and
was followed by another hospital, three were living asymp-
tomatically without treatment, two died from an accident,
and one could not be reached. 
Although one relapsed and four died among the 14 patients
in the prednisolone alone group, only one relapsed out of 11
patients in the prednisolone plus cyclophosphamide group
at one year after treatment. 
During a median follow-up of 55.5 months, 4 cases relapsed
(median: 44.5 months). However, the relapsed patients res-
ponded to increments in prednisolone dosage or the addition
of another immunosuppressant, and no further mortality
occurred among the relapsed cases. 
Eight deaths occurred during follow-up; four were vasculi-
tis-related deaths, i.e., multiorgan failure (1), subarachnoid
hemorrhage (1), and renal failure (2). Three of the patients
that succumbed had an initial FFS of 2 and one patient had
an FFS of one (Table 5). The mean age of these 4 patients at
diagnosis was 62 yr. All disease-related deaths occurred with-
in 6 months of diagnosis. Excluding a gastric cancer patient,
mortality among patients with an FFS of 2 was 33.3% (Table
5). No death was associated with a treatment related side effect.
Four deaths were unrelated to disease, i.e., lymphoma with
pneumonia (49 months after diagnosis), gastric cancer (1 mon-
th after diagnosis), and two accidental deaths (Fig. 1).
DISCUSSION
This study was conducted to investigate the clinical man-
ifestation and the course of PAN in Korean patients. All
patients were collected according to ACR criteria. Chapel
FFS
Dead
(%)
Alive
(%)
Hazard
ratio
No. of
patients
(%)
Disease related  0 10 (37) 0 (0) 10 (100) *
mortality 1 8 (30) 1 (12.5) 7 (87.5) 1.0
2 9 (33) 3 (33.3) 6 (66.6) 2.66
Total 27 4 (14.8) 23 (85.1) -
All mortality 0 10 (37) 2 (20) 8 (80) 1.0
1 8 (30) 2 (25) 6 (75) 1.25
2 9 (33) 4 (44.4) 5 (55.6) 2.22
Total 27 8 (29.6) 19 (71.4) -
Table 5. Disease related and all mortalities versus five-factor
scores (FFS)
The 5 prognostic factors are cardiomyopathy, CNS involvement, severe
GI tract symptoms, renal failure (i.e., creatinine >1.58 mg/dL), high pro-
teinuria (>1 g/day). FFS, 0 when all 5 factors are absent; FFS, 1 when
only 1 factor is present; FFS, 2 when 2 or more factors are present.
*No death.
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Fig. 1. Kaplan-Meier survival curve of polyarteritis nodosa patients.
This curve plots time to disease related death. Eight patients died
during the follow up period. Among these, 4 patients died due to
vasculitis related causes (multiorgan failure, subarachnoid hem-
orrhage, renal failure in 2 cases) within one year. Other causes of
death were lymphoma (1 case), metastatic gastric cancer (1 case),
and accidents (2 cases).Hill Consensus Conference defined PAN as necrotizing in-
flammation of medium-sized or small arteries without glo-
merulonephritis or vasculitis in arterioles, capillaries, or venules
(2). Thus patients with glomerulonephritis were not present
in our patients population. Overall clinical manifestations
and disease courses were similar to those reported by other
studies (Table 4) (8-11), which reported high incidence of
involvement of; peripheral nerve (51-75%), muscle and joint
(51%), skin (11-58%), kidney (22-66%), hypertension (14-
32%), gastrointestinal tract (25-53%), central nervous sys-
tem (2-24%), heart (4-18%), and lung (6-40%) (Table 4)
(8-11).
The reported incidence of orchitis/epididymitis by autopsy
studies vary from 60 to 80% (11, 20, 32), but symptomatic
testicular pain is an infrequent presenting manifestation of
PAN, and a few reports quote a rate of at presentation orchi-
tis/epididymitis of 2-18% (11, 20-23). Our study showed a
high rate (24%) of testicular pain or tenderness. These results
suggest that orchitis/epididymitis requires cautious checking
in Koreans in the presence of musculoskeletal symptoms,
livedo reticularis, or mono- or polyneuropathic symptoms
and signs. 
Some reports have categorized small vessel vasculitis largely
into ANCA-associated vasculitis and immune-complex vas-
culitis (13, 14). Several groups concluded after a careful his-
tological examination that ANCA is strongly correlated with
small-sized vessel involvement (7, 9, 12). ANCA-associated
vasculitis is the most common primary systemic small vessel
vasculitis in adults and includes three major categories: micro-
scopic polyangiitis, Wegener’s granulomatosis and Churg-
Strauss syndrome (7, 15-18). On the contrary, PAN is not
known to have a high positive rate of ANCA (13, 19). Our
study shows a 14% ANCA positivity rate which is compa-
rable to other foreign reports which showed up to 20%. 
Sergent et al. presented substantial evidence which indi-
cated that at least one subset of PAN patients experienced
systemic vasculitis as a result of chronic hepatitis B virus
associated immune complex disease (24). Guillevin et al. in
France in a 1981-1992 study also reported that 25-30% of
PAN patients are associated with hepatitis B, based on HBsAg
positivity (10); however, the rate in the general French popu-
lation was only 0.3% (25-27). In 1990, ACR proposed PAN
classification criteria, which included the presence of HBsAg
or HBsAb in serum as criteria (1). Recent epidemiologic data
from northeast Asian countries including Korea, China, Tai-
wan, and Japan, show that the HBsAg positive rate, even
after the 1983 global hepatitis B vaccination program was
introduced in Korea, is at 4-6%. Also, taking into consider-
ation HBsAb positive rate of 70-80%, the ACR PAN crite-
ria may produce a bias in the northeast Asian population that
causes over-diagnosis of PAN (28-31). A large scale epidemi-
ologic study may be necessary to investigate whether the high
positive rates of HBsAg and HBsAb influence the diagnosis
and prevalence of PAN in Korea. 
Old age could be an important prognostic factor. The aver-
age age of the four fatal vasculitis patients that died was 62
yr, which exceeded the total patient average age of 47.4 yr.
According to Guillevin et al., the critical period in terms of
mortality is the first year of the disease (5-7). Our study also
showed no disease related death occurred after 7 months from
the diagnosis. 
Guillevin et al. established FFS after subjecting every clini-
cal item to univariate and multivariate analyses (11), and FFS
items found to be significantly associated with an increased
mortality, namely, renal insufficiency, proteinuria and/or gas-
trointestinal tract involvement, were found to be the major
factors associated with a poor prognosis. They also suggest-
ed that renal insufficiency (Cr >1.58 mg/dL) and severe gas-
trointestinal involvement necessitating surgery are significant
predictors of death (6). In our study no disease related mor-
tality occurred in those with an FFS of 0, in contrast three of
the four disease-related mortality cases had an FFS of 2. Dis-
ease-related mortality cases showed the following items of
five factors; renal insufficiency (3 cases), cardiac involvement
(2 cases), central nervous system involvement (1 case) and
gastrointestinal tract involvement (1 case). Patients with a
higher FFS tended to have a high HR compared with those
with a lower FFS in the present study, even though statisti-
cal significance was not achieved due to the small number of
cases (Table 5). FFS may help clinicians develop a prognostic
approach to PAN and guide treatment choice (5-7).
Prednisolone based treatment is a well known treatment
modality in PAN. Sometimes a cytotoxic agent and plasma-
pheresis are added. A cytotoxic agent is indicated for patients
with disease refractory to corticosteroids or with serious major
organ involvement (7). Plasmapheresis can be performed in
fulminant disease or after the failure of another treatment
but it may facilitate infection (6, 7). Most reports on plasma-
pheresis are based on anecdotal trials or small scale studies.
Our study shows no significant difference between the sur-
vival rates of those on prednisolone alone and prednisolone
plus cytotoxic therapy. Moreover, long term treatment with
a cytotoxic agent (e.g. cyclophosphamide) may result in a
higher incidence on lymphoma or some other malignancy.
We experienced a mortality in a case with non Hodgkin’s
lymphoma and pneumonia on cyclosporine treatment. 
In conclusion, our study demonstrates that the clinical fea-
tures of polyarteritis nodosa in Korea are similar to those des-
cribed in other countries. However, the prevalence of testis
involvement appears to be high, and patients with high FFS
tended to have a poor prognosis.
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